2023 World Conference on Lung Cancer (Posters)-P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs

P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the use of lorlatinib as a first-line treatment for ALK-positive advanced non-small cell lung cancer (aNSCLC). The study aims to understand the efficacy of lorlatinib compared to other tyrosine kinase inhibitors (TKIs) in this patient population. The authors conducted an updated network meta-analysis (NMA) using recent data from the CROWN trial and ALTA-1L study. They also reviewed nine other independent NMAs to supplement the evidence. The primary analysis looked at progression-free survival (PFS) by independent radiologic review in the intent-to-treat population, while secondary outcomes included PFS in subgroups and adverse event outcomes. The results of the updated NMA were consistent with previous findings, showing that lorlatinib had significantly better PFS compared to alectinib and brigatinib. The review of the ten NMAs also supported the superior efficacy of lorlatinib over alectinib and brigatinib in terms of PFS. In patients without baseline brain metastases (BM), lorlatinib had significantly better PFS compared to brigatinib in four out of five NMAs. In patients with BM at baseline, lorlatinib showed numerically better or comparable PFS compared to alectinib and brigatinib, but these differences were not statistically significant. Overall, the findings from this study and the other NMAs support lorlatinib as an effective first-line treatment for ALK-positive aNSCLC compared to other ALK TKIs.

Asset Subtitle

Sai-Hong Ignatius Ou

Meta Tag

Speaker Sai-Hong Ignatius Ou

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

lorlatinib

first-line treatment

ALK-positive

advanced non-small cell lung cancer

tyrosine kinase inhibitors

network meta-analysis

progression-free survival

adverse event outcomes

brain metastases

CROWN trial